Literature DB >> 15225548

SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.

Ru Cao1, Yi Zhang.   

Abstract

Recent studies have revealed the intrinsic histone methyltransferase (HMTase) activity of the EED-EZH2 complex and its role in Hox gene silencing, X inactivation, and cancer metastasis. In this study, we focus on the function of individual components. We found that the HMTase activity requires a minimum of three components-EZH2, EED, and SUZ12-while AEBP2 is required for optimal enzymatic activity. Using a stable SUZ12 knockdown cell line, we show SUZ12 knockdown results in cell growth defects, which correlate with genome-wide alteration on H3-K27 methylation as well as upregulation of a number of Hox genes. Chromatin immunoprecipitation (ChIP) assay identified a 500 bp region located 4 kb upstream of the HoxA9 transcription initiation site as a SUZ12 binding site, which responds to SUZ12 knockdown and might play an important role in regulating HoxA9 expression. Thus, our study establishes a critical role of SUZ12 in H3-lysine 27 methylation and Hox gene silencing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225548     DOI: 10.1016/j.molcel.2004.06.020

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  360 in total

Review 1.  The roles and regulation of Polycomb complexes in neural development.

Authors:  Matthew Corley; Kristen L Kroll
Journal:  Cell Tissue Res       Date:  2014-11-01       Impact factor: 5.249

Review 2.  Functional Crosstalk Between Lysine Methyltransferases on Histone Substrates: The Case of G9A/GLP and Polycomb Repressive Complex 2.

Authors:  Chiara Mozzetta; Julien Pontis; Slimane Ait-Si-Ali
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

3.  Polycomb repressive complex 2 impedes intestinal cell terminal differentiation.

Authors:  Yannick D Benoit; Manon B Lepage; Taoufik Khalfaoui; Eric Tremblay; Nuria Basora; Julie C Carrier; Lorraine J Gudas; Jean-François Beaulieu
Journal:  J Cell Sci       Date:  2012-03-30       Impact factor: 5.285

4.  ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments.

Authors:  Alexander Lachmann; Huilei Xu; Jayanth Krishnan; Seth I Berger; Amin R Mazloom; Avi Ma'ayan
Journal:  Bioinformatics       Date:  2010-08-13       Impact factor: 6.937

5.  The JARID2-PRC2 duality.

Authors:  Hans-Martin Herz; Ali Shilatifard
Journal:  Genes Dev       Date:  2010-05       Impact factor: 11.361

6.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

Authors:  Christopher J Sneeringer; Margaret Porter Scott; Kevin W Kuntz; Sarah K Knutson; Roy M Pollock; Victoria M Richon; Robert A Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

7.  Distinct Cellular Assembly Stoichiometry of Polycomb Complexes on Chromatin Revealed by Single-molecule Chromatin Immunoprecipitation Imaging.

Authors:  Roubina Tatavosian; Chao Yu Zhen; Huy Nguyen Duc; Maggie M Balas; Aaron M Johnson; Xiaojun Ren
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

8.  Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation.

Authors:  Nathan D Montgomery; Della Yee; Stephanie A Montgomery; Terry Magnuson
Journal:  J Mol Biol       Date:  2007-10-22       Impact factor: 5.469

9.  Methylation of polycomb target genes in intestinal cancer is mediated by inflammation.

Authors:  Maria A Hahn; Torsten Hahn; Dong-Hyun Lee; R Steven Esworthy; Byung-Wook Kim; Arthur D Riggs; Fong-Fong Chu; Gerd P Pfeifer
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 10.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.